Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments - PubMed
3 hours ago
- #breast cancer
- #abemaciclib
- #cfDNA
- Abemaciclib, a CDK4/6 inhibitor, was studied in metastatic recurrent breast cancer patients using cfDNA analysis.
- cfDNA concentrations were higher in breast cancer patients than in healthy individuals and decreased after abemaciclib treatment.
- Sequencing revealed distinct cfDNA signatures in treated vs. untreated samples, particularly in chromatin regions linked to cell death and CDK4/6-regulated pathways.
- Differences in chromatin features were observed between long-term responders and short-term progression cases.
- Pathway analysis identified the Polycomb complex as a potential modulator of treatment efficacy, with EZH2 inhibition enhancing abemaciclib's anti-proliferative effect.
- cfDNA profiling may serve as a practical biomarker for monitoring treatment response and predicting efficacy in breast cancer therapy.